Untangling the ties that bind: the NG2-ITGA4 axis in B-ALL

This publication has 10 references indexed in Scilit:

• NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
  Blood, 2026
• KMT2A-rearranged acute lymphoblastic leukemia in infants: current progress and challenges
  Haematologica, 2025
• NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression
  Blood, 2024
• Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL
  Journal of Clinical Oncology, 2023
• Stromal-induced epithelial-mesenchymal transition induces targetable drug resistance in acute lymphoblastic leukemia
  Cell Reports, 2023
• The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
  Nature, 2023
• Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
  Journal of Clinical Oncology, 2019
• NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL
  Leukemia, 2017
• The use of natalizumab for multiple sclerosis
  Neuropsychiatric Disease and Treatment, 2017
• Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance
  Blood, 2014